Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

• DOI: 10.1111/resp.14656
• Publication Date: 2024-01-12T01:20:08Z
• Authors: John A. Mackintosh; Gregory Keir; Lauren K. Troy; Anne E. Holland; Christopher Grainge; Daniel C. Chambers; Debra Sandford; Helen E. Jo; Ian Glaspole; Margaret Wilsher; Nicole S. L. Goh; Paul N. Reynolds; Sally Chapman; Steven E. Mutsaers; Sally de Boer; Susanne Webster; Yuben Moodley; Tamera J. Corte
• Keywords: Nintedanib; Pirfenidone; Position statement; Position paper

Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia New Zealand (TSANZ) Lung Foundation (LFA) published position statement on treatment IPF. Since that time, subsidized anti‐fibrotic therapy in form pirfenidone nintedanib now available both Zealand. More recently, evidence has been support for non‐IPF (PPF). Additionally, there have numerous publications relating non‐pharmacologic management IPF PPF. This 2023 update summarizes developments since reaffirms importance multi‐faceted approach fibrosis.